Raoul S. Concepcion, M.D., F.A.C.S., has joined U.S. Urology Partners in the newly formed role of Chief Science Officer. One of the nation’s largest independent providers of urological and related specialty services, U.S. Urology Partners provides general urology, surgical procedures, advanced cancer treatment for prostate, bladder and kidney cancers, and other ancillary services.
Dr. Concepcion will lead scientific operations of the rapidly growing U.S. Urology Partners clinical network, which now includes 24 locations through partners Central Ohio Urology Group and Associated Medical Professionals of NY. Dr. Concepcion’s background includes decades of experience as a pioneer and clinician at the forefront of the industry, including serving as a founding board member and former Past President of LUGPA, the premier nonprofit association and advocate for independent urology practices.
Mark Cherney, Chief Executive Officer of U.S. Urology Partners, stated, “We are excited that Dr. Raoul Concepcion has joined U.S. Urology Partners as Chief Science Officer. His longstanding experience in urological clinical research programs and analytics will assist U.S. Urology Partners and its partner practices in providing optimal care for patients. Dr. Concepcion will be particularly helpful in advancing our precision medicine program, including genomics, genetic testing and counseling.”
As urology practices seek an alternative to hospital acquisition that will allow them to focus on the practice of medicine rather than business matters, they are turning to U.S. Urology Partners. Formed in 2018, U.S. Urology Partners supports urology practices through an experienced team of healthcare executives and resources and is funded by NMS Capital.
Raoul S. Concepcion, M.D., F.A.C.S., stated, “U.S. Urology Partners is dedicated to providing state-of-the-art care for the urologic patient by providing needed operational support and attempting to standardize care across their providers. As Chief Science Officer, I will be working alongside key physicians from the member practices to establish a precision medicine cancer management model for affiliated groups that will incorporate evidence based treatment guidelines, establish a clinical genomic medicine service and build a central clinical trials initiative. The goal is to enhance patient care and advance science, which in turn provides added value to partner practices.”
He added, “Establishing a precision medicine platform will enable the team at U.S. Urology Partners and its affiliated urology groups to deliver the correct treatment to the correct patient. The past 10 years has seen the emergence of incorporating advanced cancer management into urology practices. Now, this also mandates the understanding of genetic and genomic testing to optimize care for these patients, very much akin to the standard of care associated with breast and colorectal tumors. Thus, staying current and abreast of the rapidly evolving data presents operational challenges for the busy clinician that will be supported by U.S. Urology Partners and its Medical Advisory Team, which I am proud to be a part of.“
A native of central Ohio, Dr. Concepcion has been a Clinical Assistant Professor in the Department of Urology, Vanderbilt School of Medicine. He was a General Surgery and Urology Resident from 1984 to 1989 and served as Chief Urology Resident from 1989 to 1990. Additionally, he was a research fellow in the Light Laboratories at Vanderbilt. More recently, he has completed The City of Hope Intensive Course on Cancer Risk Assessment for hereditary cancer and genomic testing. He has been in practice since 1990, with his major clinical interest being Urologic Oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction, as well as the role of genomics and genetic testing in GU tumors. He is Board Certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeons and the Nashville Surgical Society.
From a research perspective, Dr. Concepcion has been actively in involved in basic science and clinical research since his days at Vanderbilt. Dr. Concepcion has been either the principal investigator (PI) or Co-PI on many clinical trials since the 1990s. The focus as of recent has been in advanced prostate cancer, as well as biomarker development. He co-founded CUSP, a urology specific clinical trials management company that specializes in site and patient accrual for the pharmaceutical and biolab industries. From an industry perspective, Dr. Concepcion serves as an advisor, consultant or speaker for many companies involved in the diagnosis and management of prostate cancer. He is developing a precision medicine comprehensive prostate cancer program for U.S. Urology Partners and affiliated groups, centered on genomic testing, pathway development, data aggregation and clinical trial work.
About U.S. Urology Partners
U.S. Urology Partners is one of the nation’s largest independent providers of urology and related specialty services, including general urology, surgical procedures, advanced cancer treatment, and other ancillary services. Through Central Ohio Urology Group and Associated Medical Professionals of NY, the U.S. Urology Partners clinical network now consists of 24 offices, including a state-of-the-art, urology-specific ambulatory surgery center that is one of the first in the country to offer robotic surgery. U.S. Urology Partners was formed to support urology practices through an experienced team of healthcare executives and resources, while serving as a platform upon which NMS Capital intends to build a leading provider of urological services through an acquisition strategy. The U.S. Urology Partners corporate offices are in Nolensville, Tennessee, and Gahanna, Ohio, just outside of Nashville and Columbus.
Concepcion is editor-in-chief of Urology Times' sister publication, Urologists in Cancer Care.
Original Source: US Urology Partners. https://bit.ly/2SHJgmr.